These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 26232492)

  • 61. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Immunotherapy in non-small-cell lung carcinoma: from inflammation to vaccination.
    Van den Heuvel MM; Burgers SA; van Zandwijk N
    Clin Lung Cancer; 2009 Mar; 10(2):99-105. PubMed ID: 19362952
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Constitutive and acquired mechanisms of resistance to immune checkpoint blockade in human cancer.
    Bellone M; Elia AR
    Cytokine Growth Factor Rev; 2017 Aug; 36():17-24. PubMed ID: 28606732
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
    Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J
    J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
    Durgeau A; Virk Y; Corgnac S; Mami-Chouaib F
    Front Immunol; 2018; 9():14. PubMed ID: 29403496
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.
    Łuksza M; Riaz N; Makarov V; Balachandran VP; Hellmann MD; Solovyov A; Rizvi NA; Merghoub T; Levine AJ; Chan TA; Wolchok JD; Greenbaum BD
    Nature; 2017 Nov; 551(7681):517-520. PubMed ID: 29132144
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Non-small cell lung cancer: news from immunotherapy].
    Reinmuth N; Heigener DF; Reck M
    Dtsch Med Wochenschr; 2015 Mar; 140(5):329-33. PubMed ID: 25734674
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.
    Vansteenkiste J; Zielinski M; Linder A; Dahabreh J; Gonzalez EE; Malinowski W; Lopez-Brea M; Vanakesa T; Jassem J; Kalofonos H; Perdeus J; Bonnet R; Basko J; Janilionis R; Passlick B; Treasure T; Gillet M; Lehmann FF; Brichard VG
    J Clin Oncol; 2013 Jul; 31(19):2396-403. PubMed ID: 23715567
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy.
    Hradilova N; Sadilkova L; Palata O; Mysikova D; Mrazkova H; Lischke R; Spisek R; Adkins I
    PLoS One; 2017; 12(2):e0171539. PubMed ID: 28187172
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Advances in immunotherapies for non-small cell lung cancer].
    He Y; You C
    Zhongguo Fei Ai Za Zhi; 2014 Mar; 17(3):277-81. PubMed ID: 24667269
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phase I Trial of Intratumoral Injection of
    Lee JM; Lee MH; Garon E; Goldman JW; Salehi-Rad R; Baratelli FE; Schaue D; Wang G; Rosen F; Yanagawa J; Walser TC; Lin Y; Park SJ; Adams S; Marincola FM; Tumeh PC; Abtin F; Suh R; Reckamp KL; Lee G; Wallace WD; Lee S; Zeng G; Elashoff DA; Sharma S; Dubinett SM
    Clin Cancer Res; 2017 Aug; 23(16):4556-4568. PubMed ID: 28468947
    [No Abstract]   [Full Text] [Related]  

  • 73. Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality.
    Kelly RJ; Gulley JL; Giaccone G
    Clin Lung Cancer; 2010 Jul; 11(4):228-37. PubMed ID: 20630824
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC).
    McCarthy F; Roshani R; Steele J; Hagemann T
    J Leukoc Biol; 2013 Dec; 94(6):1201-6. PubMed ID: 23695306
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Immune checkpoint inhibitors in advanced nonsmall cell lung cancer.
    Helissey C; Champiat S; Soria JC
    Curr Opin Oncol; 2015 Mar; 27(2):108-17. PubMed ID: 25602683
    [TBL] [Abstract][Full Text] [Related]  

  • 76. New strategies in lung cancer: translating immunotherapy into clinical practice.
    Forde PM; Kelly RJ; Brahmer JR
    Clin Cancer Res; 2014 Mar; 20(5):1067-73. PubMed ID: 24470514
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Vaccination therapy for non-small-cell lung cancer.
    Cuppens K; Vansteenkiste J
    Curr Opin Oncol; 2014 Mar; 26(2):165-70. PubMed ID: 24441502
    [TBL] [Abstract][Full Text] [Related]  

  • 78. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
    Meyer RG; Korn S; Micke P; Becker K; Huber C; Wölfel T; Buhl R
    Lung Cancer; 2007 Oct; 58(1):88-94. PubMed ID: 17599645
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis.
    Meng X; Gao Y; Yang L; Jing H; Teng F; Huang Z; Xing L
    Clin Lung Cancer; 2019 Jan; 20(1):48-58. PubMed ID: 30341017
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.
    Markowitz GJ; Havel LS; Crowley MJ; Ban Y; Lee SB; Thalappillil JS; Narula N; Bhinder B; Elemento O; Wong ST; Gao D; Altorki NK; Mittal V
    JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.